Centene announced changes to its executive leadership team Dec. 14 as President and COO Brent Layton takes on an advisory role as he "transitions toward retirement."
Here's a look at Centene's reshuffled executive leadership team, according to its website:
Sarah London, CEO. Ms. London was named CEO in March. She joined Centene in 2020. Her previous roles in the company include vice chair and senior vice president of technology innovation and modernization. Ms. London was a partner at Optum Ventures before joining Centene.
Ken Fasola, president. Mr. Fasola joined Centene in January with the acquisition of Magellan Health, where he served as CEO since 2019. He was Centene's executive vice president of healthcare enterprises before being named president Dec. 14.
Jim Murray, COO. Mr. Murray joined Centene as chief transformation officer in January as part of the Magellan Health acquisition. Mr. Murray served as Magellan's president and COO. He was promoted to COO Dec. 14.
Drew Asher, CFO. Mr. Asher has served as Centene's CFO since 2021. He joined the company in January 2020 after it acquired WellCare, where he served as an executive vice president.
Brent Layton, senior adviser to the CEO. Mr. Layton has been with Centene since 2006. He has overseen the development and implementation of new health plans in 19 states and provided guidance to state governments to develop Medicaid solutions.
Alice Chen, MD, chief health officer. Dr. Chen will become the payer's chief health officer on Jan. 1. She previously served as chief medical officer for Covered California, the state's health insurance marketplace.
Jon Dinesman, executive vice president of external affairs. Mr. Dinesman joined Centene in 2008. He previously worked at UnitedHealth Group and as a senior policy adviser at the Arizona House of Representatives.
Chris Koster, secretary and general counsel. Mr. Koster joined Centene in 2017 and previously served as Missouri's attorney general.
Brian LeClaire, CIO. Mr. LeClaire became Centene's CIO on Dec. 5. Before joining the payer, Mr. LeClaire was the director of technology for private equity firm Arsenal Capital Partners' healthcare team.